Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Homozygous Familial Hypercholesterolemia (ORION-5)
NCT03851705Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of inclisiran in homozygous familial hypercholesterolemia (HoFH) (3 arms), sponsored by Novartis. Primary endpoint: Percent Change in Low-Density Lipoprotein Cholesterol From Baseline at Day 150. Started Feb 2019; status: completed.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03851705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851705.